BridgeBio Pharma, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
BridgeBio Pharma, Inc. (BBIO) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-29.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-02-24
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-03-31 was $0.00.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $9.60M.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$11.95M.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2021 was -$40.83M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $21.60M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $21.60M derived: sum of 3 quarters · filed 2026-02-24 | $16.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | $21.60M derived: sum of 2 quarters · filed 2026-02-24 | $16.00M derived: sum of 3 quarters · filed 2026-02-24 | $15.79M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $21.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.00M derived: sum of 2 quarters · filed 2026-02-24 | $15.79M derived: sum of 3 quarters · filed 2026-02-24 | $9.60M 10-K · filed 2026-02-24 | $9.65M 10-K · filed 2024-02-22 |
| 2023-09-30 | -$5.60M 10-Q · filed 2024-11-12 | -$5.81M derived: sum of 2 quarters · filed 2024-11-12 | -$12.00M 10-Q · filed 2024-11-12 | -$10.62M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | -$203.00K 10-Q · filed 2024-08-01 | -$6.40M 10-Q · filed 2024-08-01 | -$5.02M derived: sum of 3 quarters · filed 2025-02-20 | $3.49M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | -$6.19M 10-Q · filed 2024-05-02 | -$4.82M derived: sum of 2 quarters · filed 2025-02-20 | $3.70M derived: sum of 3 quarters · filed 2025-02-20 | -$6.53M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $9.89M derived: sum of 2 quarters · filed 2025-02-20 | -$331.00K derived: sum of 3 quarters · filed 2025-02-20 | -$11.95M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $8.51M 10-Q · filed 2023-11-02 | -$1.71M derived: sum of 2 quarters · filed 2023-11-02 | -$13.33M 10-Q · filed 2023-11-02 | -$51.98M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | -$10.22M 10-Q · filed 2023-08-03 | -$21.84M 10-Q · filed 2023-08-03 | -$60.50M derived: sum of 3 quarters · filed 2024-02-22 | -$61.56M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | -$11.62M 10-Q · filed 2023-05-04 | -$50.28M derived: sum of 2 quarters · filed 2024-02-22 | -$51.34M derived: sum of 3 quarters · filed 2024-02-22 | ||
| 2021-12-31 | -$38.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$39.71M derived: sum of 2 quarters · filed 2024-02-22 | -$40.83M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | -$1.06M 10-Q · filed 2022-11-03 | -$2.17M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |